Initializing Vogelview...
Performing medical cross-referencing...
Initializing Vogelview...
Performing medical cross-referencing...
Loading...
Also reported in: U/mL
Your anti-Scl-70 is negative. This is the normal and reassuring result for scleroderma surveillance.
No anti-Scl-70 antibodies were detected. Anti-Scl-70 (anti-topoisomerase I) is the specific marker for diffuse cutaneous systemic sclerosis (scleroderma). A negative result makes diffuse scleroderma less likely.
No action needed.
Anti-Scl-70: negative — no anti-topoisomerase I antibodies detectedYour anti-Scl-70 is negative and within the normal reference range. This is a reassuring result for diffuse scleroderma surveillance.
No action needed.
Anti-Scl-70: negative — within reference rangeYour anti-Scl-70 is at a low-negative level with no clinically significant antibody.
No action needed.
Anti-Scl-70: low-negative — no clinically significant antibodyYour anti-Scl-70 is negative. This is the normal and reassuring result for scleroderma surveillance.
No specific action required.
Anti-Scl-70: negative — normal baselineYour anti-Scl-70 is negative, which is the optimal finding. Absence of this antibody makes diffuse scleroderma much less likely.
No action needed.
Anti-Scl-70: negative — optimal baseline for scleroderma surveillanceYour anti-Scl-70 is in the borderline-positive range. This equivocal result requires repeat testing and clinical assessment for skin thickening, Raynaud's phenomenon, and internal organ symptoms of scleroderma.
Repeat testing and rheumatology referral are recommended. Early scleroderma evaluation is important as organ involvement (lungs, kidneys) can develop insidiously.
Anti-Scl-70: borderline positive — equivocal; repeat testing recommendedYour anti-Scl-70 is positive. This antibody is found in 30–40% of patients with diffuse cutaneous systemic sclerosis and is associated with a more aggressive disease course including interstitial lung disease and scleroderma kidney situation. It is rarely seen in the absence of systemic sclerosis.
Seek rheumatology referral. Pulmonary function tests, high-resolution CT of the chest, echocardiogram, and kidney function assessment are all important components of a complete scleroderma evaluation.
Anti-Scl-70: positive — diffuse cutaneous systemic sclerosis (scleroderma) strongly associatedYour anti-Scl-70 is strongly positive, associated with diffuse systemic sclerosis that carries risk of progressive interstitial lung disease and scleroderma kidney situation. This level requires urgent specialist evaluation and organ monitoring.
Seek urgent rheumatology evaluation. Comprehensive organ assessment including pulmonary function, echocardiography, and kidney function must be arranged promptly.
Anti-Scl-70: strongly positive — aggressive diffuse scleroderma; multi-organ assessment urgentUpload your lab report and get your actual values interpreted in plain English — instantly, with no medical training required.